Owlstone Medical secured up to $49.1 million from ARPA‑H to develop an over‑the‑counter, at‑home multi‑cancer screening test able to detect more than 30 cancers at early stages. The award funds assay development, clinical validation planning and consumer deployment workstreams aimed at stage‑I detection sensitivity. Owlstone’s VOC (volatile organic compound) breath‑based technology is being adapted for a home setting to expand population screening access. ARPA‑H’s funding signals federal interest in decentralized early‑detection technologies that could shift cancer screening paradigms. Owlstone will use the financing to advance analytical validation and larger clinical studies to support regulatory filings and reimbursement conversations for an accessible screening product.